Lithium treatment alters brain activity tied to suicidal behavior in landmark study

A groundbreaking clinical trial has revealed that lithium treatment can alter brain activity linked to suicidal behaviour. The study, led by Dr. Nicholas Murphy, marks the first time such changes have been measured in humans. These findings could offer new ways to detect and intervene in cases of severe suicide risk. The research focused on patients with a history of life-threatening suicide attempts. Using electroencephalography (EEG), scientists recorded their brain activity and found heightened cortical arousal and stronger neural markers of impulsivity compared to other psychiatric patients.

Lithium was then administered to assess its impact on brain function. The results showed that the drug strengthened EEG signals tied to impulse control. This suggests improved cognitive inhibition, helping patients make more deliberate decisions rather than acting hastily.

Further analysis indicated that lithium enhances prefrontal cortex activity. This area of the brain acts as a 'braking' system, slowing down impulsive actions. The study also proposed that EEG patterns could serve as biomarkers, helping identify which patients might benefit most from lithium therapy.

Suicide remains a leading cause of death among young Americans, particularly those aged 10 to 34. Emergency departments often serve as the first point of contact for individuals in crisis, making early intervention crucial. This trial provides the first human evidence that lithium can modify brain signals associated with suicidal behaviour. The findings suggest EEG markers could help tailor treatments and monitor their effects in high-risk patients. With suicide rates remaining high, such advances may improve early detection and prevention strategies.